Frequent expression of napsin a in clear cell carcinoma of the endometrium: Potential diagnostic utility

American Journal of Surgical Pathology

Volumn 38, Issue 2, 2014, Pages 189-196

  Fadare, Oluwole ^a,k   Desouki, Mohamed M ^a   Gwin, Katja ^b   Hanley, Krisztina Z ^c   Jarboe, Elke A ^d   Liang, Sharon X ^e   Quick, Charles M ^f   Zheng, Wenxin ^g   Parkash, Vinita ^h,i   Hecht, Jonathan L ^j  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ BRIDGEPORT HOSPITAL   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

endometrial clear cell carcinoma; immunohistochemistry; napsin A

Indexed keywords

ASPARTIC PROTEINASE; NAPSA PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; ENZYMOLOGY; EVALUATION STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICAL MODEL; TISSUE MICROARRAY; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; NEOPLASM GRADING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84892958574     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000085     Document Type: Article

References (59)

1. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S105-S143.
2. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94: 642-646.
3. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004;11: 117-142.
4. Fadare O, Zheng W, Crispens MA, et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res. 2013;3:70-95.
5. Olawaiye AB, Boruta DM IInd. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113:277-283.
6. Fadare O, Renshaw IL, Liang SX. Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events. Int J Gynecol Pathol. 2011;30:252-261.
7. Lee L, Garrett L, Lee H, et al. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med. 2009;54:133-138.
8. Murphy KT, Rotmensch J, Yamada SD, et al. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1272-1276.
9. Abeler VM, Vergote IB, Kjørstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78:1740-1747.
10. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol. 2007;31:979-987.
11. Fadare O, Parkash V, Dupont WD, et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol. 2012;36:1107-1118.
12. Lewis GH, Folkins AK, Kong CS, et al. Endometrial clear cell carcinoma: incidence and clinicopathologic features [abstract]. Mod Pathol. 2013;26(suppl 2):286A.
13. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2013;37:874-881.
14. Tatnell PJ, Powell DJ, Hill J, et al. Napsins: new human aspartic proteinases. Distinction between two closely related genes. FEBS Lett. 1998;441:43-48.
15. Ueno T, Linder S, Na CL, et al. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem. 2004;279: 16178-16184.
16. Brasch F, Ochs M, Kahne T, et al. Involvement of napsin A in the C-and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem. 2003;278: 49006-49014.
17. Hirano T, Franzen B, Uryu K, et al. Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma. Br J Cancer. 1995;72:840-848.
18. Ordonez NG. Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol. 2012;19:66-73.
19. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
20. Turner BM, Cagle PT, Sainz IM, et al. Napsin A a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163-171.
21. Kadivar M, Boozari B. Applications and limitations of immuno-histochemical expression of "napsin-a" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl Immunohistochem Mol Morphol. 2013;21:191-195.
22. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
23. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
24. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.
25. Hoang LN, McConechy MK, Koebel M, et al. Histotype-genotypic correlation in 36 high-grade endometrial carcinomas [abstract]. Mod Pathol. 2013;26(suppl 2):278A.
26. Cancer Genome Atlas Research Network. Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
27. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304-315.
28. Mhawech-Fauceglia P, Herrmann FR, Rai H, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endome-trioid adenocarcinoma. Am J Clin Pathol. 2010;133:899-908.
29. Li C, Zota V, Woda BA, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007;20:1263-1268.
30. Fadare O, Liang SX, Crispens MA, et al. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol. 2013; 44:1508-1515.
31. Han G, Sidhu D, Duggan MA, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013. doi: 10.1038/modpathol.2013.102. [Epub ahead of print].
32. Yemelyanova A, Ji H, IeM Shih, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohisto-chemical analysis of 201 cases. Am J Surg Pathol. 2009;33: 1504-1514.
33. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411-432.
34. Alvarez T, Miller E, Duska L, et al. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol. 2012;36:753-761.
35. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunopheno-typic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091-1100.
36. Fadare O, Gwin K, Desouki MM, et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol. 2013;26:1101-1110.
37. Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol. 2000;13:379-388.
38. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551-558.
39. Fadare O, James S, Desouki MM, et al. Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol. 2013. doi:pii: S1092-9134(13)00036-1. 10.1016/j.anndiagpath. 2013.04.011. [Epub ahead of print].
40. Hirschowitz L, Ganesan R, WG McCluggage. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histo-pathology. 2009;55:478-482.
41. Mhawech-Fauceglia P, Yan L, Liu S, et al. ER(+)/PR(+)/TFF3(+)/IMP3(-) immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology. 2013;62:976-985.
42. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38:1074-1080.
43. Kenny SL, McBride HA, Jamison J, et al. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-p. Am J Surg Pathol. 2012;36:799-807.
44. Park KJ, Kiyokawa T, Soslow RA, et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35: 633-646.
45. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohis-tochem Mol Morphol. 2012;20:580-587.
46. Zhang PJ, Gao HG, Pasha TL, et al. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol. 2009;28:10-18.
47. Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:1759-1763.
48. Sullivan PS, Maresh EL, Seligson DB, et al. Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. Mod Pathol. 2012;25: 1140-1148.
49. Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol. 2011;35:757-761.
50. Ordonez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012;19:140-151.
51. Chernock RD, El-Mofty SK, Becker N, et al. Napsin A expression in anaplastic, poorly differentiated, and micropapillary pattern thyroid carcinomas. Am J Surg Pathol. 2013;37:1215-1222.
52. Ueno T, Elmberger G, Weaver TE, et al. The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity. Lab Invest. 2008;88:256-263.
53. Lee JG, Kim S, Shim HS. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung. Lung Cancer. 2012;77:156-161.
54. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88:1229-1233.
55. STRING database of known and predicted protein interactions. Version 8.3. Available at: http://string-db.org/newstring-cgi/show- input-page.plUserId=- wmAgdHu8Rqp&sessionId=yXGLDprgbiSa.
56. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39(Database issue):D561-D568.
57. Sati L, Seval-Celik Y, Demir R. Lung surfactant proteins in the early human placenta. Histochem Cell Biol. 2010;133:85-93.
58. Leth-Larsen R, Floridon C, Nielsen O, et al. Surfactant protein D in the female genital tract. Mol Hum Reprod. 2004;10:149-154.
59. Snegovskikh VV, Bhandari V, Wright JR, et al. Surfactant protein-A (SP-A) selectively inhibits prostaglandin F2alpha (PGF2alpha) production in term decidua: implications for the onset of labor. J Clin Endocrinol Metab. 2011;96:E624-E632.